MNPR

SEC source: 0001437749-26-032048 · rdgdoc.xml · derivative · entry 6

STARR CHRISTOPHER M · CIK 0001235470 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,400

Underlying: Common Stock · 8,400 shares

Expires 2027-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

F2 · derivative.exercise_date: On February 20, 2017, the reporting person was granted stock options to purchase up to 16,800 shares of common stock. Stock options vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter.

SEC source: 0001437749-26-032048 · rdgdoc.xml · nonDerivative · entry 4

STARR CHRISTOPHER M · CIK 0001235470 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,173

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.50 to $80.01, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

SEC source: 0001437749-26-032048 · rdgdoc.xml · nonDerivative · entry 3

STARR CHRISTOPHER M · CIK 0001235470 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,972

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

SEC source: 0001437749-26-032048 · rdgdoc.xml · nonDerivative · entry 2

STARR CHRISTOPHER M · CIK 0001235470 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,942

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

SEC source: 0001437749-26-032048 · rdgdoc.xml · nonDerivative · entry 1

STARR CHRISTOPHER M · CIK 0001235470 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,573

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.

SEC source: 0001437749-26-031924 · rdgdoc.xml · derivative · entry 3

Vu Quan Anh · CIK 0001892297 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,984

Underlying: Common Stock · 614 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F3 · derivative.exercise_date: On December 2, 2025, the reporting person was granted 9,826 restricted stock units, vesting 6/48ths (1,228) on June 30, 2026, and 3/48ths (614 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F3 · derivative.expiration_date: On December 2, 2025, the reporting person was granted 9,826 restricted stock units, vesting 6/48ths (1,228) on June 30, 2026, and 3/48ths (614 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-26-031924 · rdgdoc.xml · nonDerivative · entry 2

Vu Quan Anh · CIK 0001892297 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,655

F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

SEC source: 0001437749-26-031924 · rdgdoc.xml · nonDerivative · entry 1

Vu Quan Anh · CIK 0001892297 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,835

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-26-031925 · rdgdoc.xml · derivative · entry 4

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,602

Underlying: Common Stock · 9,801 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F4 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F6 · derivative.exercise_date: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F6 · derivative.expiration_date: On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-26-031925 · rdgdoc.xml · nonDerivative · entry 2

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,724

F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

SEC source: 0001437749-26-031925 · rdgdoc.xml · nonDerivative · entry 1

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,068

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-26-031927 · rdgdoc.xml · derivative · entry 3

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,115

Underlying: Common Stock · 4,384 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units.

F3 · derivative.exercise_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4 · derivative.exercise_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.exercise_date: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F3 · derivative.expiration_date: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4 · derivative.expiration_date: On March 4, 2025, the reporting person was granted 40,581 restricted stock units, vesting 6/48ths (5,073 shares) on June 30, 2025, and 3/48ths (2,536 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F5 · derivative.expiration_date: On December 2, 2025, the reporting person was granted 13,919 restricted stock units, vesting 6/48ths (1,740) on June 30, 2026, and 3/48ths (870 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2029. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

SEC source: 0001437749-26-031927 · rdgdoc.xml · nonDerivative · entry 2

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,054

F2 · shares: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

SEC source: 0001437749-26-031927 · rdgdoc.xml · nonDerivative · entry 1

Cittadine Andrew · CIK 0001863624 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,998

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares acquired on vesting and settlement of restricted stock units.

SEC source: 0001437749-26-031411 · rdgdoc.xml · derivative · entry 9

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,204

Underlying: Common Stock · 15,000 shares

Expires 2032-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted stock options to purchase up to 42,204 shares of common stock. Stock options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.

SEC source: 0001437749-26-031411 · rdgdoc.xml · derivative · entry 8

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,044

Underlying: Common Stock · 14,056 shares

Expires 2028-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

F2 · derivative.exercise_date: On August 9, 2018, the reporting person was granted stock options to purchase up to 29,100 shares of common stock. Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.

SEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 6

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,267

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.56 to $89.91, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

SEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 5

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,867

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.54 to $89.51, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

SEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 4

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,235

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.54 to $88.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

SEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 3

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,873

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.54 to $87.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.

SEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 2

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,323

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

SEC source: 0001437749-26-031411 · rdgdoc.xml · nonDerivative · entry 1

Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,323

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026.

SEC source: 0001437749-26-029121 · rdgdoc.xml · derivative · entry 3

RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,380 shares

Expires 2026-12-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

F2 · derivative.exercise_date: On December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of common stock vested: 238 shares on January 15, 2017; 224 shares on February 15, 2017; 238 shares on March 15, 2017; 224 shares on April 15, 2017; 238 shares on May 15, 2017; and 238 shares on June 15, 2017.

SEC source: 0001437749-26-029121 · rdgdoc.xml · nonDerivative · entry 2

RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,065

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

SEC source: 0001437749-26-029121 · rdgdoc.xml · nonDerivative · entry 1

RIOUX PATRICE · CIK 0001241033 · Acting Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,066

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

SEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 6

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,396

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.

SEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 5

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,986

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.

SEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 4

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,588

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.

SEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 3

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,686

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.

SEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 2

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,386

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.

SEC source: 0001437749-26-029116 · rdgdoc.xml · nonDerivative · entry 1

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,001

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/27/2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.

SEC source: 0001437749-26-029235 · rdgdoc.xml · derivative · entry 11

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,140

Underlying: Common Stock · 2,035 shares

Expires 2029-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

F3 · derivative.exercise_date: On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.

SEC source: 0001437749-26-029235 · rdgdoc.xml · derivative · entry 10

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,165

Underlying: Common Stock · 2,055 shares

Expires 2028-08-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

F2 · derivative.exercise_date: On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.

SEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 8

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

SEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 7

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 590

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

SEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 6

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,192

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

SEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 5

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,290

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

SEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 4

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,990

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

SEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 3

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,605

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

SEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 2

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

SEC source: 0001437749-26-029235 · rdgdoc.xml · nonDerivative · entry 1

Tsuchimoto Kim R · CIK 0001333516 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

SEC source: 0001437749-26-029115 · rdgdoc.xml · nonDerivative · entry 3

Anderson Raymond · CIK 0001362489 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,751

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/26/2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.

SEC source: 0001437749-26-029115 · rdgdoc.xml · nonDerivative · entry 2

Anderson Raymond · CIK 0001362489 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,523

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/26/2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.

SEC source: 0001437749-26-029115 · rdgdoc.xml · nonDerivative · entry 1

Anderson Raymond · CIK 0001362489 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,169

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on 05/26/2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.

SEC source: 0001437749-26-029228 · rdgdoc.xml · derivative · entry 7

Anderson Raymond · CIK 0001362489 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,480

Underlying: Common Stock · 1,740 shares

Expires 2028-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.

F3 · derivative.exercise_date: On August 9, 2018, the reporting person was granted stock options to purchase up to 5,220 shares of common stock. The options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.

SEC source: 0001437749-26-029228 · rdgdoc.xml · derivative · entry 6

Anderson Raymond · CIK 0001362489 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,803

Underlying: Common Stock · 1,402 shares

Expires 2027-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.

F2 · derivative.exercise_date: On September 18, 2017, the reporting person was granted stock options to purchase up to 4,205 shares of common stock. The options vest 6/42nds at the six-month anniversary of grant date and 1/42nd per month thereafter.

SEC source: 0001437749-26-029228 · rdgdoc.xml · nonDerivative · entry 5

Anderson Raymond · CIK 0001362489 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,373

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.84 to $113.11, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

SEC source: 0001437749-26-029228 · rdgdoc.xml · nonDerivative · entry 4

Anderson Raymond · CIK 0001362489 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,175

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.56 to $111.41, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

SEC source: 0001437749-26-029228 · rdgdoc.xml · nonDerivative · entry 3

Anderson Raymond · CIK 0001362489 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,821

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.51 to $110.43, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.

SEC source: 0001437749-26-029228 · rdgdoc.xml · nonDerivative · entry 2

Anderson Raymond · CIK 0001362489 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,515

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 26, 2026.